PROCEPT BioRoboticsPRCT +1.16%70 Gross Margin % is 64.89% as of Mar. 2026, which is 31% above its 10-year median of 49.44. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $91.98 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 805 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks better than 69.57% on this metric.
The historical rank and industry rank for PROCEPT BioRobotics's Gross Margin % or its related term are showing as below:
PRCT'
s Gross Margin % Range Over the Past 10 Years
Min: -30.56 Med: 49.44 Max: 63.97
Current: 63.97
During the past 7 years, the highestGross Margin % of PROCEPT BioRobotics was 63.97%. The lowest was -30.56%. And the median was 49.44%.
PRCT's Gross Margin % is ranked better than 69.57% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 52.07
vs PRCT: 63.97
PROCEPT BioRobotics had a gross margin of 64.89% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for PROCEPT BioRobotics was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
PROCEPT BioRobotics had a gross margin of 64.89% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
PROCEPT BioRobotics Gross Margin % Related Terms
PROCEPT BioRobotics Gross Margin % Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRCT vs ALMR, AHCO, ENOV: Gross Margin % Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
PROCEPT BioRobotics (PRCT) has a Gross Margin % of 64.89% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on PROCEPT BioRobotics and its competitors. This is 31% above median its historical median of 49.44. According to the industry distribution chart, PROCEPT BioRobotics ranks #245 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 30.4%.
Is PROCEPT BioRobotics' Gross Margin % too high?
PROCEPT BioRobotics' current Gross Margin % of 64.89% is 31% above median its 10-year median of 49.44. The Medical Devices & Instruments industry median Gross Margin % is 52.07. PROCEPT BioRobotics' value of 64.89% is 24.6% above this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #245 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Gross Margin % compare to ALMR and AHCO?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #245 out of 805 companies for Gross Margin %. This puts PROCEPT BioRobotics in the upper half of its industry. The industry median Gross Margin % is 52.07. PROCEPT BioRobotics' value of 64.89% is 24.6% above this benchmark. While the company's 10-year median is 49.44 vs. the industry median of 52.07, PROCEPT BioRobotics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current Gross Margin % of 64.89% is 24.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current Gross Margin % is 64.89%, which is 31% above median its own 10-year median of 49.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $91.98, compared to a current price of $20.85 — trading 77.3% below its estimated fair value. The current Gross Margin % is 64.89%, which is 31% above median its 10-year median of 49.44 and 24.6% above the Medical Devices & Instruments industry median of 52.07. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Gross Margin % is 64.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $20.85 is trading 77.3% below its estimated GF Value™ of $91.98.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
Gross Margin %: 64.89% (31% above median its 10-year median of 49.44)
GF Value™: $91.98 vs. price of $20.85 (77.3% below fair value)
Industry Position: 24.6% above the Medical Devices & Instruments median (#245 of 805)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
